Itolizumab Causes Equillium’s Skyrocketing Stock (EQ)

Mostly biotech companies make news during the COVID-19 crisis and even small success may cause a significant rise in the majority of stocks. Dexamethasone and remdesivir gave some effects on stock indexes too.

Already existing itolizumab significantly reduced mortality in patients hospitalized with COVID-19 in India. Equillium’s (NASDAQ: EQ) partner Biocon is testing itolizumab which is developed to treat severe autoimmune and inflammatory disorders. Its opponents such as dexamethasone, avifavir and remdesivir already showing positive effects on treating COVID-19 patients but the completely striking vaccine doesn’t exist and possible creation may occur in 2021.

Equillium (EQ) more than triples with the change from $3.19 to $15.40 by rising volume to over 58 million shares. After several successful clinical trials of itolizumab EQ might soar higher again.

Alex Krakowsky

Editor in Chief. Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life